Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Descending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
69539-0034-01 69539-0034 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use
57277-0106-15 57277-0106 carboplatin Injection Carboplatin 150.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 29, 2016 In Use
31722-0165-31 31722-0165 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous July 29, 2021 In Use
00006-3941-01 00006-3941 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 19, 2010 In Use
00006-3941-32 00006-3941 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 12, 2010 In Use
00781-3484-75 00781-3484 Fosaprepitant dimeglumine Fosaprepitant dimeglumine 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 16, 2022 In Use
68001-0523-36 68001-0523 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 2, 2022 In Use
67184-0540-01 67184-0540 Fosaprepitant dimeglumine FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 8, 2020 In Use
67457-0889-10 67457-0889 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use
69097-0830-37 69097-0830 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use
71839-0104-01 71839-0104 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Oct. 15, 2019 In Use
70710-1615-01 70710-1615 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 1, 2020 In Use
63323-0972-10 63323-0972 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use
55150-0299-01 55150-0299 Fosaprepitant dimeglumine Fosaprepitant dimeglumine 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 12, 2021 In Use
72205-0026-01 72205-0026 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 In Use
72205-0083-01 72205-0083 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous May 12, 2020 In Use
70625-0300-01 70625-0300 Fosaprepitant Dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 5, 2019 In Use
72603-0106-01 72603-0106 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 Oct. 1, 2022 No Longer Used
71731-5111-01 71731-5111 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 16, 2021 In Use
16729-0240-03 16729-0240 FOSAPREPITANT Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Oct. 22, 2020 In Use
25021-0784-10 25021-0784 Fosaprepitant Dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Dec. 15, 2019 In Use
59651-0523-01 59651-0523 Fosaprepitant dimeglumine Fosaprepitant dimeglumine 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 12, 2021 In Use
70860-0780-10 70860-0780 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 30, 2019 Sept. 30, 2021 No Longer Used
72606-0569-01 72606-0569 Fosaprepitant Dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 1, 2020 In Use
00006-3061-00 00006-3061 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 3, 2017 In Use
00006-3061-01 00006-3061 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 3, 2017 In Use
00006-3061-04 00006-3061 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 3, 2017 May 25, 2021 In Use
00006-3061-02 00006-3061 Fosaprepitant Dimeglumine Emend 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 3, 2017 May 16, 2021 In Use
00781-3497-75 00781-3497 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 2, 2020 Feb. 29, 2024 No Longer Used
68001-0421-22 68001-0421 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 20, 2019 In Use
68180-0690-01 68180-0690 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 25, 2020 Jan. 31, 2024 No Longer Used
82238-0018-01 82238-0018 FOSAPREPITANT DIMEGLUMINE FOSAPREPITANT DIMEGLUMINE 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 12, 2021 In Use
70860-0783-10 70860-0783 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous March 15, 2021 July 31, 2024 In Use
81952-0911-01 81952-0911 FOSAPREPITANT FOSAPREPITANT 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous July 14, 2023 In Use
68001-0517-36 68001-0517 fosaprepitant fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 23, 2021 July 31, 2024 In Use
60505-6105-01 60505-6105 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 5, 2019 Nov. 30, 2023 No Longer Used
70860-0782-10 70860-0782 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 30, 2020 Jan. 31, 2023 No Longer Used
71288-0418-10 71288-0418 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov. 15, 2019 March 30, 2023 No Longer Used
16714-0248-01 16714-0248 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 28, 2023 In Use
83634-0776-10 83634-0776 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Feb. 28, 2024 In Use
82243-1001-01 82243-1001 FOSAPREPITANT FOCINVEZ 150.0 mg/50mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug. 30, 2023 In Use
50742-0446-15 50742-0446 Carboplatin Carboplatin 150.0 mg/15mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 6, 2017 Feb. 12, 2018 In Use
00054-0271-21 00054-0271 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 15, 2016 In Use
00093-7473-06 00093-7473 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 7, 2014 In Use
16714-0467-01 16714-0467 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 1, 2015 In Use
50242-0064-01 50242-0064 Erlotinib Hydrochloride Tarceva 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2005 In Use
54868-5447-00 54868-5447 Erlotinib Hydrochloride Tarceva 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 13, 2005 In Use
61958-1702-01 61958-1702 Idelalisib Zydelig 150.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral July 23, 2014 In Use
00078-0592-51 00078-0592 Nilotinib Tasigna 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct. 29, 2007 In Use
00078-0592-87 00078-0592 Nilotinib Tasigna 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Oct. 29, 2007 In Use
62559-0173-31 62559-0173 Nilutamide Nilutamide 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 18, 2016 In Use
00088-1111-14 00088-1111 Nilutamide Nilandron 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Sept. 19, 1996 March 31, 2015 No Longer Used
00591-4385-79 00591-4385 fosaprepitant Fosaprepitant 150.0 mg/1 Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sept. 19, 2019 In Use
42292-0053-05 42292-0053 Erlotinib hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 28, 2019 Jan. 31, 2021 No Longer Used
59923-0727-30 59923-0727 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 1, 2020 In Use
68382-0915-06 68382-0915 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0915-16 68382-0915 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68382-0915-84 68382-0915 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-03 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-07 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
70771-1523-09 70771-1523 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2020 In Use
68001-0487-06 68001-0487 CAPECITABINE CAPECITABINE 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 22, 2021 In Use
50242-0140-01 50242-0140 Vismodegib Erivedge 150.0 mg/1 Chemotherapy Hedgehog Pathway Inhibitor SMO Oral Jan. 30, 2012 In Use
50242-0140-86 50242-0140 Vismodegib Erivedge 150.0 mg/1 Chemotherapy Hedgehog Pathway Inhibitor SMO Oral April 9, 2013 In Use
55111-0496-05 55111-0496 capecitabine capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
55111-0496-60 55111-0496 capecitabine capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 10, 2020 In Use
62756-0238-18 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0238-86 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
62756-0238-88 62756-0238 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2019 In Use
63304-0135-11 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0135-30 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
72606-0554-01 72606-0554 Capecitabine Capecitabine 150mg 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Nov. 6, 2019 In Use
70756-0815-60 70756-0815 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Sept. 1, 2020 In Use
69539-0092-30 69539-0092 Erlotinib Hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
72205-0082-30 72205-0082 Erlotinib Hydrochloride Erlotinib Hydrochloride 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 11, 2021 In Use
72485-0219-30 72485-0219 Erlotinib hydrochloride Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 6, 2019 In Use
66993-0212-38 66993-0212 Nilutamide Nilutamide 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral Nov. 22, 2019 In Use
00093-7664-56 00093-7664 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 In Use
00002-5337-54 00002-5337 Abemaciclib Verzenio 150.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral Oct. 6, 2017 In Use
00002-5337-63 00002-5337 Abemaciclib Verzenio 150.0 mg/1 Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Oral March 5, 2020 In Use
69539-0019-60 69539-0019 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 2, 2018 In Use
69539-0019-99 69539-0019 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral July 2, 2018 In Use
72485-0204-60 72485-0204 Capecitabine Capecitabine 150mg 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 1, 2019 In Use
00310-0679-12 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0679-60 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 17, 2017 In Use
00310-0679-95 00310-0679 Olaparib Lynparza 150.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Aug. 31, 2017 In Use
59651-0204-10 59651-0204 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 17, 2018 In Use
59651-0204-60 59651-0204 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 17, 2018 In Use
00078-0708-02 00078-0708 Alpelisib PIQRAY 150.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
00078-0708-91 00078-0708 Alpelisib PIQRAY 150.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
00004-1100-20 00004-1100 Capecitabine Xeloda 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 30, 1998 In Use
00004-1100-75 00004-1100 Capecitabine Xeloda 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral April 30, 1998 Dec. 31, 2014 In Use
00078-0694-48 00078-0694 ceritinib ZYKADIA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral March 18, 2019 In Use
00078-0694-84 00078-0694 ceritinib ZYKADIA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral March 18, 2019 In Use
42291-0166-60 42291-0166 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral May 11, 2018 Nov. 19, 2018 In Use
42291-0190-60 42291-0190 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 20, 2015 March 19, 2018 No Longer Used
54868-4143-00 54868-4143 Capecitabine Xeloda 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 20, 2005 In Use
63759-3000-01 63759-3000 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Dec. 31, 2016 In Use
16729-0072-12 16729-0072 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral June 9, 2015 In Use
50242-0130-01 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Dec. 11, 2015 In Use

Found 10,000 results in 15 milliseconds — Export these results